Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.66 |
| ▸ | FEN1 | P39748 | 14/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 7/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634507 | 0.83 | EGLN1 (0.67) | EGLN1FEN1ERCC5 | |
| SCHEMBL2493231 | 0.80 | EGLN1 (1.00) | EGLN1KCNH2 | |
| SCHEMBL14034799 | 0.80 | EGLN1 (0.70) | EGLN1KCNH2 | |
| SCHEMBL10080435 | 0.79 | EGLN1 (0.62) | EGLN1FEN1ERCC5KCNH2 | |
| SCHEMBL2493854 | 0.78 | EGLN1 (0.61) | EGLN1 | |
| SCHEMBL2497674 | 0.76 | ALDH1A1 (0.61) | EGLN1FEN1 | |
| SCHEMBL14034795 | 0.76 | EGLN1 (0.72) | EGLN1FEN1ERCC5KCNH2 | |
| SCHEMBL2502552 | 0.76 | EGLN1 (0.53) | EGLN1FEN1ERCC5 | |
| SCHEMBL2441282 | 0.76 | EGLN1 (0.69) | EGLN1 | |
| SCHEMBL4492683 | 0.73 | MEN1 (0.66) | EGLN1FEN1ERCC5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150251-B9 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2150251-B9 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2013-02-27 | — | — | EP | disclosed |
| EP-2150251-B1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2150251-B1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030346-B2 | Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-06-18 | — | — | US | disclosed |
| WO-2008137060-A1 | THIENOPYRIDINE AND THIAZOLOPYRIDINE DERIVATIVES THAT INHIBIT PROLYL HYDROXYLASE ACTIVITY | AMGEN INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156633-A1 | Heterocyclic quinolone derivatives that inhbit prolyl hydroxylase activity | EGLN3, HIF1AN, EGLN2 | EGLN1 6/4885FEN1 2052/4885ERCC5 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.